Prospective multicenter evaluation of the Beckman coulter prostate health index using WHO calibration

Journal of Urology

Volumn 189, Issue 5, 2013, Pages 1702-1706

  Loeb, Stacy ^a   Sokoll, Lori J ^b   Broyles, Dennis L ^c   Bangma, Chris H ^e   Van Schaik, Ron H N ^e   Klee, George G ^f   Wei, John T ^g   Sanda, Martin G ^h   Partin, Alan W ^b   Slawin, Kevin M ⁱ   Marks, Leonard S ^d   Mizrahi, Isaac A ^c   Shin, Sanghyuk S ^c   Cruz, Amabelle B ^c   Chan, Daniel W ^b   Roberts, William L ^j   Catalona, William J ^k  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BECKMAN COULTER INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ Texas Prostate Center   (United States)

^j ARUP LABORATORIES   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

biological assays; biopsy; mass screening; prostate; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BECKMAN COULTER PROSTATE HEALTH INDEX; CALIBRATION; CANCER DIAGNOSIS; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

BIOLOGICAL MARKERS; CALIBRATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; WORLD HEALTH ORGANIZATION;

EID: 84876287137     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.11.149     Document Type: Article

References (12)

1. M.J. Barry Screening for prostate cancer - the controversy that refuses to die N Engl J Med 360 2009 1351
2. W.J. Catalona, A.W. Partin, K.M. Slawin Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial JAMA 279 1998 1542
3. S.D. Mikolajczyk, W.J. Catalona, C.L. Evans Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer Clin Chem 50 2004 1017
4. W.J. Catalona, A.W. Partin, M.G. Sanda A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650
5. F.H. Jansen, M. Roobol, C.H. Bangma Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection Clin Chem 54 2008 1999
6. W.J. Catalona, C.G. Ramos, G.F. Carvalhal Lowering PSA cutoffs to enhance detection of curable prostate cancer Urology 55 2000 791
7. L.J. Sokoll, D.W. Chan, G.G. Klee Multi-center analytical performance evaluation of the Access Hybritech(R) p2PSA immunoassay Clin Chim Acta 413 2012 1279
8. W.J. Catalona, D.S. Smith, T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 1991 1156
9. S.A. Kort, F. Martens, H. Vanpoucke Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation Clin Chem 52 2006 1568
10. S. Loeb, D.W. Chan, L. Sokoll Prostate specific antigen assay standardization bias could affect clinical decision making J Urol 180 2008 1959
11. C. Stephan, M. Klaas, C. Muller Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update Clin Chem 52 2006 59
12. G. Guazzoni, L. Nava, M. Lazzeri Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting Eur Urol 60 2011 214